1. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges
- Author
-
Regine Eibl, Dieter Eibl, Christian van den Bos, and Valentin Jossen
- Subjects
0301 basic medicine ,Microcarrier ,Technology Assessment, Biomedical ,Computer science ,Process (engineering) ,Clinical scale ,Bioreactor ,Cell Culture Techniques ,Cell- and Tissue-Based Therapy ,660.6: Biotechnologie ,Human mesenchymal stem cell ,Applied Microbiology and Biotechnology ,Regenerative medicine ,Human mesenchymal stem cells ,03 medical and health sciences ,Bioreactors ,Humans ,Good manufacturing practice ,Advanced therapeutic medicinal product ,Allogeneic ,Mesenchymal stem cell ,Single-use device ,Mesenchymal Stem Cells ,General Medicine ,Mini-Review ,equipment and supplies ,Single-Use Device ,Single-use devices ,030104 developmental biology ,Cell culture technique ,Biochemical engineering ,Biotechnology ,Biomedical technology assessment - Abstract
Human mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures based on instrumented single-use bioreactors have been shown to provide billion of cells with consistent product quality and to be superior to traditional expansions in planar cultivation systems. Furthermore, under consideration of the complex nature and requirements of allogeneic hMSC-therapeutics, a new equipment for downstream processing (DSP) was successfully evaluated. This mini-review summarizes both the current state of the hMSC production process and the challenges which have to be taken into account when efficiently producing hMSCs for the clinical scale. Special emphasis is placed on the upstream processing (USP) and DSP operations which cover expansion, harvesting, detachment, separation, washing and concentration steps, and the regulatory demands.
- Published
- 2018